Suchergebnisse - "Plested, Joyce S"

PubPharm (55)

1

Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial

enthalten in: bioRxiv.org | 2024

von Bennett, C. | Rivers, E. | Woo, W. | +22

2

Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose : interim analysis of a phase 3, non-inferiority, randomised, clinical trial

enthalten in: The Lancet. Infectious diseases | 2024

von Bennett, C. | Woo, W. | Bloch, M. | +95

3

Altered IgG4 antibody response to repeated mRNA versus recombinant protein SARS-CoV-2 vaccines

enthalten in: The Journal of infection | 2024

von Kalkeri, R. | Zhu, M. | Cloney-Clark, S. | +12

UpdateOf: medRxiv. 2024 Jan 18;:. - PMID 38293205

4

A Pseudovirus-Based Neutralization Assay for SARS-CoV-2 Variants : A Rapid, Cost-Effective, BSL-2-Based High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation

enthalten in: Microorganisms | 2024

von Cai, Z. | Kalkeri, R. | Zhu, M. | +9

5

Altered IgG4 Antibody Response to Repeated mRNA versus Protein COVID Vaccines

enthalten in: bioRxiv.org | 2024

von Kalkeri, R. | Zhu, M. | Cloney-Clark, S. | +12

6

Altered IgG4 Antibody Response to Repeated mRNA versus Protein COVID Vaccines

enthalten in: medRxiv : the preprint server for health sciences | 2024

von Kalkeri, R. | Zhu, M. | Cloney-Clark, S. | +12

UpdateIn: J Infect. 2024 Feb 13;88(3):106119. - PMID 38360356

7

Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines : a phase 3, randomized, clinical trial

enthalten in: The Journal of infectious diseases | 2023

von Bennett, C. | Rivers, E. | Woo, W. | +22

8

A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults

enthalten in: Scientific reports | 2023

von Kulkarni, P. | Gunale, B. | Kohli, S. | +41

9

Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary Vaccination

enthalten in: The Journal of infectious diseases | 2023

von Fries, L. | Formica, N. | Mallory, R. | +30

10

Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in India : A Phase 2-3 Randomized Clinical Trial

enthalten in: JAMA pediatrics | 2023

von Gunale, B. | Kapse, D. | Kar, S. | +50

1
2
3
4
5
6
Nächster »
[6]